Prima Biomed Ltd Enters Agreement with Fraunhofer Institute for Cell Therapy and Immunology
News Jun 01, 2010
The preparation for production of CVac™ for the European trial has already commenced, and Prima BioMed Ltd and the Fraunhofer IZI are working together to prepare the facility to support CVac™ clinical trials in Europe in early 2011. This represents a significant milestone on the pathway to commercialization of CVac™ in the European market.
In addition the agreement with Fraunhofer provides a number of other key benefits to Prima BioMed Ltd. Fraunhofer is among the foremost R&D institutes in Europe and it has strong collaborative networks throughout academia, government, and industry. Fraunhofer will help enhance the visibility of the CVac™ clinical program in Europe and globally.
Prima Chief Operating Officer and Managing Director for Europe, Matthew Lehman said: “The Fraunhofer Institute is among the foremost research and development organizations in the world and Prima is delighted to enter into this collaborative arrangement (…)”.
Fraunhofer IZI Head of Cell Therapy Production, Dr. Gerno Schmiedeknecht, commented: “Cell therapies are a cutting-edge technology with the potential to significantly benefit patients. The Fraunhofer IZI is at the forefront of this technology in Europe and we are very excited to help develop Prima’s CVac™.”
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018